SLE manifestations at diagnosis. Treatment during the first 4 months after diagnosis.
| Criteria | 97acr Cohort, n = 58 (%) | 82acr Cohort, n = 81 (%) | OR | 95% CI |
|---|---|---|---|---|
| Malar rash | 35 (60) | 43 (53) | 1.35 | 0.7–2.7 |
| Discoid rash | 18 (31) | 48 (59) | 0.31 | 0.2–0.6 |
| Photosensitivity | 30 (52) | 53 (65) | 0.57 | 0.3–1.1 |
| Oral ulcers | 12 (21) | 25 (31) | 0.58 | 0.3–1.3 |
| Arthritis | 31 (54) | 67 (83) | 0.24 | 0.1–0.5 |
| Serositis | 11 (19) | 21 (26) | 0.67 | 0.3–1.5 |
| Renal disorder | 7 (12) | 27 (33) | 0.28 | 0.1–0.7 |
| Proteinuria | 5 (9) | 24 (31) | 0.22 | 0.1–0.6 |
| Casts | 6 (10) | 16 (20) | 0.47 | 0.2–1.3 |
| Neurological disorder | 1 (2) | 5 (5) | 0.27 | 0.0–2.4 |
| Hematological disorder | 27 (47) | 62 (77) | 0.27 | 0.1–0.6 |
| Leukopenia | 16 (28) | 42 (52) | 0.35 | 0.2–0.7 |
| Lymphopenia | 15 (26) | 47 (58) | 0.25 | 0.1–0.5 |
| Immunological disorder | 43 (74) | 57 (70) | 1.21 | 0.6–2.8 |
| LE cells | 0 (0) | 27 (33) | — | — |
| Anti-DNA antibodies | 39 (67) | 36 (44) | 2.57 | 1.3–5.2 |
| Anti-Sm antibodies | 6 (10) | 8 (10) | 1.05 | 0.4–3.2 |
| False-positive syphilis test | 5 (9) | 7 (9) | 1.00 | 0.3–3.3 |
| aPL | 15 (26) | 1 (1) | 27.9 | 3.6–218 |
| Antinuclear antibodies | 53 (95) | 78 (96) | 0.41 | 0.1–1.8 |
| Azathioprine | 8 (14) | 2 (3) | 6.32 | 1.3–31.0 |
| Methylprednisolone | 6 (10) | 1 (1) | 9.23 | 1.1–78.9 |
| Low-dose aspirin | 12 (21) | 0 (0) | 20.9 | 2.6–165.7 |
For abbreviations see Table 1.